KEAP1 and multiple sclerosis: Nrf2-activating compounds are currently being tested in clinical trials or are already in clinical use, such as dimethyl fumarate (Tecfidera), an Nrf2 pathway inhibitor used for the treatment of multiple sclerosis.25 Further studies are necessary to examine whether Nrf2 overexpression or activation of the Nrf2/Keap-1 system could improve the effect of ADSCs on the viability of fat grafts.